MedTrace Logo

Anti-Diabetic Medications to Fight PD and LBD

NCT06263673 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.

Conditions

  • Lewy Body Dementia
  • Parkinson Disease

Interventions

DRUG

Sitagliptin

100 mg once daily, oral

DRUG

Dapagliflozin

10 mg once daily, oral

DRUG

Placebo

Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.

Sponsors & Collaborators

Principal Investigators

  • Jessica Wilson, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-07
Primary Completion
2025-01-08
Completion
2025-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06263673 on ClinicalTrials.gov